Evidence map›Paper›PMID 35145789›Full record

ArticleCureus2022

Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects.

Rameez Zaman, Elliott Goldberg, Naseem Zomorodi, Vinita J Acharya

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rameez ZamanNeurology, Penn State College of Medicine, Hershey, USA.
Elliott GoldbergNeurology, Penn State College of Medicine, Hershey, USA.
Naseem ZomorodiNeurology, Penn State College of Medicine, Hershey, USA.
Vinita J AcharyaNeurology/Epilepsy, Penn State College of Medicine, Hershey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dalfampridine is a drug used to improve walking in multiple sclerosis (MS) patients. Approved in 2010, it is contraindicated in patients who have a history of seizures and/or renal disease. In this case report, we present a patient who did not have either of these contraindications yet had a seizure episode with the only contributing factor being the use of dalfampridine.

Indexed as

ampyradalfampridinefaersmsms drugmultiple sclerosisrisk of seizureseizure

Identifiers

PMID35145789
PMCPMC8808083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.